ESMO TAT 2021 | Unmet needs in cellular therapy manufacturing

Vered Caplan, BSc, Orgenesis, Germantown, MD, gives an overview of chimeric antigen receptor T-cell (CAR-T) therapies, commenting on the needs for improved manufacturing and on novel approaches. Ms Caplan also discusses work being done by Orgenesis in the production of dendritic vaccines. This interview took place during the ESMO TAT 2021 conference.